Chlamydia: Clinical Trials

8 trials for Chlamydia, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

4 completed, 2 recruiting, 1 active not recruiting, 1 not yet recruiting. 8 Phase 4.

By phase and status

PhaseTrialsStatus
Phase 48Completed 4, Recruiting 2, Active not recruiting 1, Not yet recruiting 1

Follow Chlamydia: new trials by email Literature Review of Chlamydia trials Research Report on Chlamydia

Trials (filtered) newest first · largest first

All 8 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Daily, Weekly, or Event-driven Doxycycline for STI Prevention Among Men Who Have Sex With Men (MSM) Engaging in Chemsex: The DOSE Non-inferiority Trial
On demand doxycycline hyclate 200mg, Daily doxycycline hyclate 100mg, Weekly doxycycline hyclate 100mg - Gonorrhea, Chlamydia
Phase 4Not yet recruitingUniversity of California, Los Angeles3002026-11-012026-11-09
Doxycycline Prophylaxis for Prevention of Sexually Transmitted Infections
Doxycycline hyclate delayed released 200 mg, Doxycycline hyclate delayed released 200 mg weekly, Per standard of care with quarterly STI testing/treatment and sexual health counseling - Gonorrhea, Chlamydia
Phase 4RecruitingWestat7602026-02-272026-10-16
The Efficacy of Doxycycline Post Exposure Prophylaxis for Preventing STIs Among MSM in Bangkok, Thailand.
Doxycycline (200mg/day) - Syphilis Infection, Gonorrhea
Phase 4RecruitingBangrak STIs Center4002025-10-062026-02-09
Superiority of On-demand PrEP Versus PEP on Using Doxycycline for Preventing STI in MSM
DoxyODPrEP, DoxyPEP - Sexually Transmitted Diseases, Bacterial, Syphilis
Phase 4Active not recruitingChinese University of Hong Kong3002025-03-292026-06-05
Evaluation of Doxycycline Post-exposure Prophylaxis to Reduce Sexually Transmitted Infections in PrEP Users and HIV-infected Men Who Have Sex With Men
Doxycycline Hyclate Delayed-Release 200 mg - Gonorrhea, Chlamydia
Phase 4CompletedUniversity of California, San Francisco6412019-11-262024-07-12
Tripartite International Research for the Elimination of Trachoma
mass treatment with oral azithromycin - Trachoma, Chlamydia
Phase 4CompletedUniversity of California, San Francisco290002010-11-012017-10-11
Trachoma Amelioration in Northern Amhara (TANA)
Mass treatment with oral azithromycin to an entire community - Trachoma, Chlamydia
Phase 4CompletedUniversity of California, San Francisco330002006-06-012015-09-09
Trachoma Elimination Follow-up
Mass treatment with oral azithromycin to an entire village - Trachoma, Chlamydia
Phase 4CompletedUniversity of California, San Francisco200002003-03-012015-07-15

Narrower conditions

Chlamydia Infections (8)  ·  Gonorrhea (5)  ·  Syphilis (5)  ·  Sexually Transmitted Diseases (4)  ·  Trachoma (3)  ·  Bacterial Infections (2)  ·  Eye Diseases (2)  ·  Homosexuality (2)  ·  Sexually Transmitted Diseases, Bacterial (1)

Broader conditions

Bacterial Infections and Mycoses (8)  ·  Chlamydiaceae Infections (8)  ·  Communicable Diseases (8)  ·  Genital Diseases (8)  ·  Gram-Negative Bacterial Infections (8)  ·  Infections (8)  ·  Urogenital Diseases (8)  ·  Sexually Transmitted Diseases, Bacterial (7)  ·  Bacterial Infections (6)  ·  Neisseriaceae Infections (5)  ·  Spirochaetales Infections (5)  ·  Treponemal Infections (5)  ·  Disease Attributes (4)  ·  Pathologic Processes (4)  ·  Pathological Conditions, Signs and Symptoms (4)

Interventions

Azithromycin (1)  ·  Doxycycline (1)  ·  Therapeutics (1)

Sponsors

University of California, San Francisco (4)  ·  Bangrak STIs Center (1)  ·  Chinese University of Hong Kong (1)  ·  University of California, Los Angeles (1)  ·  Westat (1)

Countries

Ethiopia (3)  ·  United States (3)  ·  Hong Kong (1)  ·  Thailand (1)

Top investigators

Kieran S O'Brien, MPH (2)  ·  Paul Emerson, PhD (2)  ·  Tom Lietman, MD (2)  ·  Anne Luetkemeyer, MD (1)  ·  Cherie Blair, MD, PhD (1)  ·  Cherie Blaire, MD, PhD (1)  ·  Jenell Stewart, DO, MPH (1)  ·  Thomas M Lietman, MD (1)  ·  Tsz Ho Kwan, PhD (1)

Results publications

PMID 37018493, PMID 19329003, PMID 21685340, PMID 22095569, PMID 22192488, PMID 22736616, PMID 24621121, PMID 29229440, PMID 30106956, PMID 31166952, PMID 33835852, PMID 34143341, PMID 34392717, PMID 34852691, PMID 37021692, PMID 38118022, PMID 38656217, PMID 38797183, PMID 39363100, PMID 40147465, PMID 40637301

NIH funding

R01AI143439 (1), R01DA066392 (1), UM2HD111076 (1), UM2HD111102 (1)